Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| 제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
|---|---|---|---|---|---|
| GMP-ACAH37 | Human | GMP Human Activin A / INHBA Protein |  |
||
| ACA-H5314 | Human | Human Activin A / INHBA Protein, premium grade |  |
|
|
| ACA-H421b | Human | Human Activin A / INHBA Protein, Tag Free |  |
|
|
| ACA-H424x | Human | Human Latent Activin A / INHBA Protein, His Tag |  |
|
Human Activin A Protein, premium grade (Cat. No. ACA-H5314) stimulates Human Activin RIl (Luc) HEK293 Reporter Cell. The specific activity of Human Activin A Protein, premium grade is＞5.00 x 10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (QC tested).
Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) inhibits the proliferation of MPC-11 cells. The specific activity of Human Activin A Protein, Tag Free is > 5.00×10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (Routinely tested).
Human Activin RIIB, His Tag (Cat. No. ACB-H5226) immobilized on CM5 Chip can bind Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) with an affinity constant of 0.216 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Momelotinib Dihydrochloride | CYT-387; GS-0387; GSK-3070785 | Approved | Ojjaara, Omjjara | United States | Primary Myelofibrosis; Anemia | Glaxosmithkline Llc, Glaxosmithkline Plc | 2023-09-15 | Polycythemia; Polycythemia Vera; Anemia; Neoplasms; Myeloproliferative Disorders; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Splenomegaly; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BLU-782 | BLU-782; IPN-60130 | Phase 2 Clinical | Blueprint Medicines Corp, Ipsen SA | Myositis Ossificans | Details |
| Zilurgisertib | INCB-000928; INCB-00928 | Phase 2 Clinical | Incyte Corp | Anemia; Polycythemia Vera; Myelodysplastic Syndromes; Kidney Diseases; Ossification, Heterotopic; Multiple Myeloma; Myositis Ossificans; Primary Myelofibrosis; Thrombocythemia, Essential | Details |
| KER-047 | KER-047 | Phase 1 Clinical | National Center For Advancing Translational Sciences | Anemia, Iron-Deficiency; Myositis Ossificans | Details |
| Itacnosertib | TP-0184 | Phase 1 Clinical | Tolero Pharmaceuticals Inc, Sumitomo Dainippon | Solid tumours; Anemia | Details |
| BCX-9250 | BCX-9250 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | Myositis Ossificans | Details |
This web search service is supported by Google Inc.
A-Z
